Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(43%)
Terminated
1(14%)

Phase Distribution

Ph not_applicable
3
43%
Ph phase_2
2
29%
Ph phase_3
2
29%

Phase Distribution

0

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(6)
Terminated(1)

Detailed Status

Recruiting3
Not yet recruiting3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (28.6%)
Phase 32 (28.6%)
N/A3 (42.9%)

Trials by Status

terminated114%
recruiting343%
not_yet_recruiting343%

Recent Activity

3 active trials
Showing 5 of 7
recruitingnot_applicable

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

NCT03977571
not_yet_recruitingnot_applicable

Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

NCT07233668
recruitingphase_3

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

NCT04510597
recruitingphase_2

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

NCT04322955
not_yet_recruitingphase_2

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

NCT06279403
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03977571Not Applicable

Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial

Recruiting
NCT07233668Not Applicable

Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

Not Yet Recruiting
NCT04510597Phase 3

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Recruiting
NCT04322955Phase 2

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

Recruiting
NCT06279403Phase 2

Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Not Yet Recruiting
NCT05941169Not Applicable

Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy

Not Yet Recruiting
NCT02535351Phase 3

Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery

Terminated

All 7 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
7